Related Experiment Video

Updated: May 9, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis

Katie R Hagen1, Xiangbin Zeng1, Mi-Young Lee1

  • 1Department of Radiation Oncology, Emory University School of Medicine, Atlanta, USA.

Cell Division
|July 27, 2013
PubMed
Abstract

Insights

Targeting cyclin-dependent kinase 4 (CDK4) sensitizes breast cancer cells to radiotherapy by enhancing apoptosis. Silencing CDK4 increases radiation-induced cell death, offering a potential strategy to overcome radioresistance in breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Breast cancer treatment relies on molecular markers, but acquired therapy resistance remains a challenge.
  • Evidence points to the G1 phase regulatory machinery's deregulation in therapy resistance.
  • Understanding resistance mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate if G1 phase regulatory machinery deregulation contributes to radiotherapy resistance in breast cancer.
  • To identify specific molecular targets for overcoming radioresistance.

Main Methods:

  • Irradiation of human mammary epithelial and breast cancer cell lines (ER-PR-Her2+, ER-PR-Her2-).
  • Assessment of radioresistance via colony formation assays.
  • Analysis of cell cycle, DNA replication, mitosis, apoptosis, and DNA breaks using immunocytochemistry, Western blots, and flow cytometry.
  • Generation of cell lines with silenced CDK2 and CDK4 using small hairpin RNA (shRNA).

Main Results:

  • Overexpression of cyclin A1 and cyclin D1, impacting CDK2 and CDK4 activity, was observed in all cell lines.
  • Silencing CDK4, but not CDK2, significantly sensitized breast cancer cells to radiation.
  • A CDK4/CDK6 inhibitor induced apoptosis in MDA-MB-468 cells upon irradiation.
  • CDK4 silencing increased radiation-induced apoptosis without significantly altering cell cycle progression or DNA repair.
  • Lower levels of phospho-Bad at ser136 were observed upon CDK4 silencing and irradiation, indicating apoptosis signaling.

Conclusions:

  • Knockdown of CDK4 activity sensitizes breast cancer cells to radiation.
  • This sensitization is mediated by the activation of apoptosis pathways.
  • Targeting CDK4 represents a potential therapeutic strategy to enhance radiotherapy efficacy in breast cancer.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...